Appajosyula Sireesh 4/A
4/A · Tharimmune, Inc. · Filed Oct 9, 2024
Insider Transaction Report
Form 4/AAmended
Tharimmune, Inc.THAR
Appajosyula Sireesh
DirectorCEO
Transactions
- Purchase
Common Stock
2024-10-08$1.93/sh+5,000$9,650→ 5,758 total
Holdings
- 2,593(indirect: See footnote)
Common Stock
- 21(indirect: See footnote)
Common Stock
Footnotes (1)
- [F1]2,593 shares of common stock are held indirectly by Highpoint Pharmaceuticals, LLC and 21 shares of common stock are held by Channel BioConsulting LLC. The Reporting Person is the managing member of each of Highpoint Pharmaceuticals, LLC and Channel BioConsulting LLC and in such capacity has the right to vote and dispose of the securities held by such entities.